Patents Assigned to Beacon Laboratories, Inc.
-
Publication number: 20040157924Abstract: Methods of using propionoyloxymethyl propionate (“POMP”) and butyroyloxymethyl butyrate (“BOMB”) are disclosed. Methods of treating an illness, including cancer, hemological disorders and inherited metabolic disorders, as well as other conditions, using these compounds are disclosed. The compounds are effective in the inhibition of histone deacetylase.Type: ApplicationFiled: February 3, 2004Publication date: August 12, 2004Applicant: Beacon Laboratories, Inc., a Maryland corporationInventors: Hsuan-Yin Lan-Hargest, Norbert L. Wiech
-
Patent number: 6720445Abstract: Novel acetyloxymethyl esters are disclosed. Methods of treating an illness, including cancer, hemological disorders and inherited metabolic disorders, and treating or ameliorating other conditions using these compounds are also disclosed. The compounds are effective in the inhibition of histone deacetylase.Type: GrantFiled: December 21, 2000Date of Patent: April 13, 2004Assignee: Beacon Laboratories, Inc.Inventors: Hsuan-Yin Lan-Hargest, Norbert L. Wiech
-
Patent number: 6699902Abstract: Novel acetyloxymethyl esters are disclosed. Methods of treating an illness, including cancer, hemological disorders and inherited metabolic disorders, and treating or ameliorating other conditions using these compounds are also disclosed. The compounds are effective in the inhibition of histone deacetylase.Type: GrantFiled: January 28, 2002Date of Patent: March 2, 2004Assignee: Beacon Laboratories, Inc.Inventors: Hsuan-Yin Lan-Hargest, Norbert L. Wiech
-
Patent number: 6693132Abstract: Methods of using propionoyloxymethyl propionate (“POMP”) and butyroyloxymethyl butyrate (“BOMB”) are disclosed. Methods of treating cancer using these compounds are disclosed. The compounds are effective in the inhibition of histone deacetylase.Type: GrantFiled: December 21, 2000Date of Patent: February 17, 2004Assignee: Beacon Laboratories, Inc.Inventors: Hsuan-Yin Lan-Hargest, Norbert L. Wiech
-
Publication number: 20040029922Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-ketoepoxide group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or to stimulate hematopoietic cells ex vivo.Type: ApplicationFiled: May 21, 2003Publication date: February 12, 2004Applicant: Beacon Laboratories, Inc.Inventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman
-
Publication number: 20040029903Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, a trihalomethylcarbonyl group, such as a trifluoromethylcarbonyl group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or for stimulating hematopoietic cells ex vivo.Type: ApplicationFiled: May 21, 2003Publication date: February 12, 2004Applicant: Beacon Laboratories, Inc.Inventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman
-
Publication number: 20040023944Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-chalcogenmethylcarbonyl group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or for stimulating hematopoietic cells ex vivo.Type: ApplicationFiled: May 21, 2003Publication date: February 5, 2004Applicant: Beacon Laboratories, Inc.Inventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman
-
Patent number: 6667341Abstract: Amidomethyl esters, carbonylmercaptomethyl esters, keto-containing esters, amidomethyl thioesters, amidomethyl amides, and methylene dithioesters are disclosed. The novel compounds have two carbonyl groups connected by a linking moiety having an oxygen, sulfur or nitrogen attached to a methylene group, to which is further attached a sulfur, nitrogen or CH2 group. Methods of treating illnesses and conditions, such as cancer, hemological disorders, inherited metabolic disorders and others, using these compounds are also disclosed.Type: GrantFiled: May 17, 2001Date of Patent: December 23, 2003Assignee: Beacon Laboratories, Inc.Inventors: Hsuan-Yin Lan-Hargest, Norbert L. Wiech
-
Publication number: 20030171409Abstract: Amidomethyl esters, carbonylmercaptomethyl esters, keto-containing esters, amidomethyl thioesters, amidomethyl amides, and methylene dithioesters are disclosed. The novel compounds have two carbonyl groups connected by a linking moiety having an oxygen, sulfur or nitrogen attached to a methylene group, to which is further attached a sulfur, nitrogen or CH2 group. Methods of treating illnesses and conditions, such as cancer, hemological disorders, inherited metabolic disorders and others, using these compounds are also disclosed.Type: ApplicationFiled: October 29, 2002Publication date: September 11, 2003Applicant: Beacon Laboratories, Inc, a Delaware corporationInventors: Hsuan-Yin Lan-Hargest, Norbert L. Wiech
-
Patent number: 6599937Abstract: The invention relates to methods of modulating gene expression in a hematopoietic cell or augmenting hematopoiesis in a host, as well as methods of treating, preventing, or ameliorating disorders affecting hematopoiesis level in a host, by administering to the host or the hematopoietic cell an effective amount of a compound of formula (I).Type: GrantFiled: September 25, 2000Date of Patent: July 29, 2003Assignee: Beacon Laboratories, Inc.Inventors: Edward Neiss, Bernard Loev
-
Patent number: 6562995Abstract: Amidomethyl esters, carbonylmercaptomethyl esters, keto-containing esters, amidomethyl thioesters, amidomethyl amides, and methylene dithioesters are disclosed. The novel compounds have two carbonyl groups connected by a linking moiety having an oxygen, sulfur or nitrogen attached to a methylene group, to which is further attached a sulfur, nitrogen or CH2 group. Methods of treating illnesses and conditions, such as cancer, hemological disorders, inherited metabolic disorders and others, using these compounds are also disclosed.Type: GrantFiled: December 21, 2000Date of Patent: May 13, 2003Assignee: Beacon Laboratories, Inc.Inventors: Hsuan-Yin Lan-Hargest, Norbert L. Wiech
-
Patent number: 6239176Abstract: This invention relates to compositions for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, augmenting expression of tumor suppressor genes, inducing tolerance to antigens, or treating, preventing or ameliorating protozoan infection or inhibiting histone deacetylase in cells. The compositions of the invention are to and the methods of the invention use hydroxy and ether-containing oxyalkylene esters.Type: GrantFiled: February 15, 2000Date of Patent: May 29, 2001Assignees: Beacon Laboratories, Inc., Bar-Ilan University, Mor Research Applications, Ltd.Inventors: Abraham Nudelman, Ada Rephaeli
-
Patent number: 6130248Abstract: This invention relates to compositions for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, augmenting expression of a tumor suppressor gene and inducing tolerance to an antigen. The methods of the invention use tricarboxylic acid substituted oxyalkyl esters.Type: GrantFiled: December 30, 1996Date of Patent: October 10, 2000Assignees: Bar-ILAn University, Mor Research Applications, Ltd., Beacon Laboratories, Inc.Inventors: Abraham Nudelman, Ada Rephaeli
-
Patent number: 6124495Abstract: This invention relates to compositions for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, modulating gene expression and particularly augmenting expression of a tumor suppressor gene and inducing tolerance to an antigen. The methods of the invention use unsaturated oxyalkylene esters.Type: GrantFiled: March 11, 1997Date of Patent: September 26, 2000Assignee: Beacon Laboratories, Inc.Inventors: Edward Neiss, Bernard Loev
-
Patent number: 6110955Abstract: This invention relates to compositions for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, modulating gene expression and particularly augmenting expression of a tumor suppressor gene, inducing tolerance to an antigen and treating, ameliorating or preventing protozoan infection. The methods of the invention use metabolically stabilized oxyalkylene esters.Type: GrantFiled: March 11, 1997Date of Patent: August 29, 2000Assignee: Beacon Laboratories, Inc.Inventors: Abraham Nudelman, Ada Rephaeli, Edward Neiss, Bernard Loev
-
Patent number: 6110970Abstract: This invention relates to nitrogen-containing oxyalkylene diester compositions for treating disease conditions including cancer and other proliferative diseases. The nitrogen-containing oxyalkylene diesters are represented by the formula ##STR1## where the nitrogen-containing group is R.sub.3 and includes particular alkyl, alkenyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl or heteroaryl groups, which have nitrogen-containing substituents, such as amines, amides, or nitrogen heteroatoms.Type: GrantFiled: March 11, 1997Date of Patent: August 29, 2000Assignees: Beacon Laboratories, Inc., Mor Research Applications, Ltd., Bar-Ilan UniversityInventors: Abraham Nudelman, Ada Rephaeli
-
Patent number: 6043389Abstract: This invention relates to compositions for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dedendent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, augmenting expression of tumor suppressor genes, inducing tolerance to antigens, or treating, preventing or ameliorating protozoan infection or inhibiting histone deacetylase in cells. The compositions of the invention are to and the methods of the invention use hydroxy and ether-containing oxyalkylene esters.Type: GrantFiled: March 11, 1997Date of Patent: March 28, 2000Assignees: Mor Research Applications, Ltd., Beacon Laboratories, Inc., Bar-Ilan UniversityInventors: Abraham Nudelman, Ada Rephaeli
-
Patent number: 5939455Abstract: This invention provides a method of augmenting the therapeutic activity of an oxyalkylene-containing compound, butyric acid, a butyric acid salt or butyric acid derivative by administering an inhibitor of .beta.-oxidation of fatty acids to a patient or to host cells. Pharmaceutical compositions are also included.Type: GrantFiled: March 11, 1997Date of Patent: August 17, 1999Assignee: Beacon Laboratories, Inc.Inventor: Ada Rephaeli
-
Patent number: 5330469Abstract: An apparatus for supporting an electrosurgical generator (14) and interfacing the generator (14) with an electrosurgical pencil (40, 234, or 254) and a supply of inert gas to allow gas-enhanced electrosurgery. One embodiment generally includes an accessible platform (134) for supporting the generator (14), a receiving area (146) for containing a supply of inert gas, an adaptor (142) for receiving an electrosurgical pencil interconnected with the supply of inert gas, and an interface structure (210) which allows an operator, through use of a control device, to control the flow of gas and electrical output to the pencil. Consequently, existing generators may be used with the present invention to conduct gas-enhanced electrosurgery.Type: GrantFiled: April 5, 1991Date of Patent: July 19, 1994Assignee: Beacon Laboratories, Inc.Inventor: Richard P. Fleenor
-
Patent number: 5306238Abstract: An electrosurgical apparatus (10) is disclosed wherein the electrode (12) and nozzle (14) can be maintained in a nested arrangement when the apparatus (10) is in inactive operation, such as when the electrode (12) is being positioned for surgery or when the apparatus (10) is not in use. The apparatus (10) may be employed for gas-enhanced electrosurgery with the electrode (12) and nozzle (14) in the nested arrangement, the apparatus (10) thereby functioning as a dual mode, conventional electrosurgery and gas-enhanced electrosurgery, instrument. Embodiments are disclosed which are adapted for laparoscopic applications.Type: GrantFiled: September 13, 1991Date of Patent: April 26, 1994Assignee: Beacon Laboratories, Inc.Inventor: Richard P. Fleenor